News

Zacks Investment Research on MSN10h
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...
Sickle cell gene therapy offers hope to N.J. teen
New gene therapy improves the life of 18-year-old with Sickle Cell Disease which affects 5,000 New Jersey residents living ...
Annual Alzheimer's clinical trials pipeline report shows increased reason for optimism
An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the ...
Zacks Investment Research on MSN9h
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing ...
Best Momentum Stock to Buy for June 4th
Here is the stock with buy rank and strong momentum characteristics for investors to consider today, June 4th: BioCryst Pharmaceuticals BCRX: This company which is a leader in the use of ...